STAT

NOVEMBER 12, 2023

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease. Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed  reductions in LDL-C levels of

312

312

Safe Biologics

NOVEMBER 12, 2023

ASBM Whitepaper to Examine Impact of Medicare Drug Price-Setting on Drug Development, Patient Access The Journal of the Generics and Biosimilars Initiative (GaBI) is currently finalizing a whitepaper based on the July 26th webinar hosted by ASBM and GaBI entitled MEDICARE DRUG PRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines.

Biosimilars 130

Biosimilars Drug Pricing Packaging Labelling 130

STAT

NOVEMBER 12, 2023

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients. Among patients with atrial fibrillation, an abnormal heart rhythm that increases the risk of stroke, abelacimab, developed by Anthos Therapeutics, cut the overall risk of bleeding by 67% compared to rivaroxaban, the blood thinner sold as Xarelto by Janssen P

277

277

Safe Biologics

NOVEMBER 12, 2023

On November 6, 2023, the Centers for Medicare and Medicaid Services (CMS) announced a proposed Rule that would permit Medicare Part D plan sponsors to substitute non-interchangeable biosimilars in place of the biologic medicines now used to treat many chronic conditions such as rheumatoid arthritis, Crohn’s disease and cancer. The policy change represents a stark departure from the perspectives of the U.S. medical community and patient advocacy organizations, a decade of state-level policymaking

Biosimilars 113

Biosimilars 113

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

pharmaphorum

NOVEMBER 12, 2023

AHA: Wegovy improves survival in outcomes trial Phil.

111

111

Express Pharma

NOVEMBER 12, 2023

Zydus Lifesciences was able to successfully launch its homegrown NCE drugs Oxemia (desidustat) and Lipaglyn (saroglitazor) in the Indian market. It also partnered with Sun Pharma and Lupin to co-market desidustat and saroglitazar, respectively, in the Indian market. These partnerships will help improve the market penetration of these drugs in India, says GlobalData.

Diabetes 105

Diabetes 105

BioPharma Dive

NOVEMBER 12, 2023

Early clinical trial results are the first for a base editing treatment and show Verve’s therapy can substantially lower cholesterol levels by editing the genes of liver cells.

83

83

Drug Patent Watch

NOVEMBER 12, 2023

In a recent article in Pharmaceutical Executive, Alan Kalton, Senior Vice President of Commercial Strategy at Aktana, sheds light on the critical challenges facing pharmaceutical companies as they confront impending… The post AI-Driven Strategies: Pharma’s Answer to Patent Expirations appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceutical Companies 97

Pharmaceutical Business Review

NOVEMBER 12, 2023

A clinical stage pipeline asset for the company , LP-310 is intended to be indicated for inflammatory diseases of the oral cavity, including oral lichen planus and oral GvHD. Earlier, LP-10 received ODD from the FDA, thereby making LP-310 the second of the company’s leading product candidates to receive this designation. LP-310 liposomal tacrolimus is an oral rinse formulation of the company’s lead drug candidate, LP-10.

Immunity 59

Immunity Immunization 59

Drug Patent Watch

NOVEMBER 12, 2023

Acetylcysteine is the generic ingredient in seven branded drugs marketed by Cumberland Pharms, Aspen, Eugia Pharma, Exela Pharma, Fresenius Kabi Usa, Indoco, Rising, Sagent Pharms Inc, Steriscience, Zydus Pharms, Alvogen,… The post New tentative approval for Rising drug acetylcysteine appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

Pharmacy Times

NOVEMBER 12, 2023

The American Heart Association published a statement describing the cardiovascular-kidney-metabolic (CKM) construct, specifically highlighting treatment challenges for CKM syndrome.

58

58

Drug Patent Watch

NOVEMBER 12, 2023

Annual Drug Patent Expirations for SKYLA Skyla is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There are six patents… The post New patent expiration for Bayer Hlthcare drug SKYLA appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharmacy Joe

NOVEMBER 12, 2023

In this episode, I’ll discuss haloperidol for ICU delirium. Episode 869: Three Recent Studies About Haloperidol and ICU Delirium Subscribe on iTunes , Android , or Stitcher Despite efforts to reduce the incidence of ICU delirium with light sedation techniques, many patients still end up with delirium during their stay in the ICU. Some of these patients develop agitated delirium that requires treatment so the patient does not harm themselves or staff caring for them.

Hospitals 52

Hospitals Inpatient Labelling 52

Drug Patent Watch

NOVEMBER 12, 2023

Annual Drug Patent Expirations for KYLEENA Kyleena is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There are six patents… The post New patent expiration for Bayer Hlthcare drug KYLEENA appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

Pharmacy Joe

NOVEMBER 12, 2023

In this episode, I’ll discuss haloperidol for ICU delirium. Episode 869: Three Recent Studies About Haloperidol and ICU Delirium Subscribe on iTunes , Android , or Stitcher Despite efforts to reduce the incidence of ICU delirium with light sedation techniques, many patients still end up with delirium during their stay in the ICU. Some of these patients develop agitated delirium that requires treatment so the patient does not harm themselves or staff caring for them.

Hospitals 52

Hospitals Inpatient Labelling 52

Drug Patent Watch

NOVEMBER 12, 2023

AMRIX (cyclobenzaprine hydrochloride) Teva pharms intl Patent: 7,829,121 Expiration: Nov 14, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact… The post Drug Patent Expirations for the Week of November 12, 2023 appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Med Ed 101

NOVEMBER 12, 2023

In this case scenario, I review the possibility of venlafaxine withdrawal and some key factors that lead me to this assessment. A 59-year-old patient presents to your pharmacy seeking a refill for her Klonopin prescription and to purchase a pill organizer for herself. Upon discussing with her, she reports a slight fever, chills, and fatigue […] The post Venlafaxine Withdrawal – Case Study appeared first on Med Ed 101.

52

52

Pharma in Brief

NOVEMBER 12, 2023

The Patented Medicine Prices Review Board ( PMPRB ) has released a scoping paper on themes and questions to develop new price review Guidelines. The scoping paper also includes information on how stakeholders can participate in the consultation. The deadline for written submissions addressing the scoping paper is December 20, 2023. Background The PMPRB has not had a full set of Guidelines since July 1, 2022, when amendments to the Patented Medicines Regulations came into force implementing a

Drug Pricing 52

Drug Pricing Documentation 52

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.